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Methicillin-resistant Staphylococcus aureus (MRSA) is a serious pathogen that is resistant to current antibiotic therapy. Thus, there is an urgent need for novel 
antimicrobial agents that can effectively combat these new strains of drug-resistant “superbugs”. Recently, fractionation of an extract from Platanus 
occidentalis (American sycamore) leaves produced an active kaempferol molecule, 3-O-alpha-L-(2",3"-di-p-coumaroyl)rhamnoside (KCR), in four isomeric 
forms; all four isomers exhibit potent anti-MRSA activity. In order to further the preclinical development of KCR as a new antibiotic class, we developed and 
validated a simple analytical method for assaying KCR plasma concentration. Because KCR will be developed as a new drug, although comprising four 
stereoisomers, the analytical method was devised to assay the total amount of all four isomers. In the present work, both a plasma processing procedure and an 
HPLC method have been developed and validated. Mouse plasma containing KCR was first treated with ethanol and then centrifuged. The supernatant was 
dried, suspended in ethanol, centrifuged, and the supernatant was injected into an HPLC system comprising a Waters C18, a mobile phase composing 
methanol, acetonitrile, and trifluoroacetic acid and monitored at 313 nm. The method was validated by parameters including a good linear correlation, a limit 
of quantification of 0.27 µg/mL, and high accuracy. In summary, this method allows a rapid analysis of KCR in the plasma samples for pharmacokinetics 
studies. 
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Methicillin-resistant Staphylococcus aureus (MRSA) is a serious 
pathogen that can resist conventional antibiotic therapy. MRSA 
causes patient mortality and extends hospital stays, resulting in 
higher healthcare costs; MRSA alone is estimated to kill around 
19,000 people every year in the U.S. [1, 2]. Further, MRSA has 
recently emerged as a community-associated pathogen (CA-
MRSA), infecting individuals who have not been hospitalized or 
undergone a medical procedure within the last year [3]. MRSA is 
also known to be a common skin colonizer and causes the same 
spectrum of infections as methicillin-susceptible S. aureus (MSSA) 
infections. Over 50% of Staphylococcus cases around the world are 
known to be caused by MRSA [4]. 
 
Currently, vancomycin is widely used as the drug of choice for 
MRSA infections even though it is only successful in 35-57% of the 
infections [5]. Vancomycin has to be administered by i.v. 
injection/infusion, which may require prolonged hospitalization. 
Oral antibiotic choices for MRSA include trimethoprim-
sulfamethoxazole (TMP-SMX), clindamycin, doxycycline, 
minocycline, linezolid and rifampin. TMP-SMX is a sulfonamide 
antibiotic used as the initial antibiotic for CA-MRSA infection, but 
it is associated with several potentially serious adverse reactions 
and is not suitable for general use [6]. Clindamycin is another 
antibiotic frequently used as an initial therapeutic option, but 
resistance to clindamycin can develop rapidly [7,8]. Doxycycline 
and minocycline also have been reported to be effective antibiotics 
for MRSA/CA-MRSA [9, 10]. Linezolid has been used in central 
nervous system (CNS) MRSA infections and has similar efficacy as 
vancomycin. Its oral bioavailability allows oral administration thus 
decreasing hospital stays and therapy costs [11]. Rifampin has been 
used in combination with other antibiotics, such as TMP-SMX, 
clindamycin, or doxycycline/minocycline since resistance may 
develop rapidly if it is used as monotherapy [12]. However, the 
most effective anti-MRSA drug used currently is daptomycin, a 
cyclic lipopeptide derived from Streptomyces roseosporus. 
Daptomycin is useful in treatments of short duration and persistent 
MRSA un-affected by other drug treatments [13]. Its mechanism of 
action involves binding to the bacterial cell membrane, which 
causes depolarization of the membrane potential leading to 
inhibition of bacterial growth. Unfortunately, the FDA has reported 
serious side effects for daptomycin, including an increase in blood 
creatine phosphokinase, rhabdomyolysis, skin exfoliation and skin 
ulcers. Thus, there are great and urgent needs for novel 
antimicrobial agents that can effectively combat these new strains 
of drug-resistant “superbugs” [14]. One of the most promising 
sources of anti-MRSA agents is from natural products. 
 
Currently, 60-75% of pharmaceutical sales for infectious diseases 
and cancer are from products derived from natural sources and 
approximately 60% of those compounds commercially available or 
in the late stages of clinical trials for the treatment of infectious 
diseases or cancer are of natural product origin [15]. Rapid 
emergence of multi drug-resistant microbial pathogens is a serious 
problem to US human health.  
 
Platanaceae is a family of flowering plants, which has a long 
history of use in traditional folk medicines as antimicrobial and 
antiseptic herbal remedies. Platanus occidentalis, also known as 
American sycamore, is one of the species of Platanus native to 
North America [16]. Sycamore material has been widely used in 
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folk medicine [17]. Native Americans used sycamore for various 
medicinal purposes, including cold and cough remedies, as well as 
dermatological, respiratory and gastrointestinal aids. Sycamore bark 
is currently taken as a dietary aid to gain weight and as an analgesic 
for internal pains. Sycamore extracts also have been used in 
cosmetic preparations and as an antidiarrheal for dysentery [18]. 
The extensive human contact and use of this plant has led to the 
classification of sycamore material as generally regarded as safe 
(GRAS) by the US FDA. 
 
American sycamore is a native US species already in culture for 
timber and pulp production. As a result, leaf material for drug 
production will be highly scalable. In a recent study, Ibrahim et al. 
isolated a group of glycosides from the leaf extract of         
American sycamore [5]. Fractionation of the extract produced       
an active kaempferol molecule, 3-O-alpha-L-(2",3"-di-p-
coumaroyl)rhamnoside (KCR), in four stereoisomeric forms (EE, 
EZ, ZE, and ZZ) (Figure 1). All four isomers exhibit potent anti-
MRSA activity, both in cultures and in animal models [5,19]. 
Active metabolites of these anti-MRSA extracts are likely to 
possess a novel mechanism of action as they do not show cross-
resistance or structural homology with established antibiotics. This 
represents the first plant-derived antibiotics to prevent growth of 
MRSA both on surfaces and systemically.  
 
 
 
 
Figure 1: Structures of the four stereoisomers of KCR 
 
In order to further the preclinical development of KCR as an 
antibiotic for MRSA, we have developed and validated an analytical 
method suitable for assaying plasma concentration of KCR. 
Because KCR will be developed as a new antibiotic in that all four 
isomers are active, the analytical method was developed to assay 
the total amount of all four isomers.  
 
Experimental 
 
Instruments: A Waters Alliance HPLC system [including a Waters 
2690 Separations Module, a Waters 2996 Photodiode Array 
Detector, a Waters C18 column, and the Waters Empower software] 
(Milford, Massachusetts, USA) was used in this study for the 
determination of KCR. A Beckman Coulter Allegra 21R Centrifuge 
(Fullerton, California, USA) was employed to prepare the plasma 
and plasma samples for HPLC injection, and an Eppendorf 
Vacufuge™ to evaporate the solvent during the sample prep. 
 
Reagents: KCR (HPLC peak purity >99 %) was extracted and 
purified as previously described [5]. Individual stereoisomers (KCR 
in EE, EZ, ZE, and ZZ forms) were provided by Dr Jim McChesney 
(Ironstone Separations, Inc., MS). All solvents were HPLC grade 
and obtained from Burdick & Jackson (Muskegon, Michigan, 
USA).  
Preparation of control plasma samples:  Control mouse blood 
samples were collected by cardiac puncture using a 1 mL syringe 
(with a 25-gauge needle) containing heparin as anticoagulant.  Once 
the maximum amount of blood was collected, it was transferred to a 
1.5 mL conical centrifuge tube and centrifuged at 14,000 rpm 
(equivalent to 19,280 g) at 4ºC for 15 min to separate plasma and 
red blood cells (RBC).  Plasma was transferred and stored in a 
freezer at -20ºC.  To prepare individual spiked standards, 50 µL of 
KCR stock solutions in ethanol were added individually to 200 µL 
of plasma samples, and 800 µL of ethanol was then added to each 
vial. Each aliquot was vortexed for 10 sec and centrifuged at 14,000 
rpm for 15 min at room temperature.  Each supernatant was 
removed and collected in a 1.5 mL conical Eppendorf® tube and 
evaporated to dryness employing an Eppendorf Vacufuge® at 45ºC.  
The residue was reconstituted in 200 µL of ethanol, centrifuged, 
and the supernatant was injected (10 µL injection) into the HPLC 
system. To prepare a plasma control, 4x of ethanol (v/v) was added 
to each plasma sample, and processed in the same way as the spiked 
plasma standards before HPLC analysis. 
 
HPLC procedure: KCR in the eluted fraction was determined using 
a Waters Nova-Pak® C18 reversed-phase column (3.9 x 300 mm) 
with a 4 m particle size.  The injection volume was 10 L; the 
column oven was at room temperature; the mobile phase was 
methanol/acetonitrile/aqueous formic acid (0.3%), 60/3/37, v/v, at a 
flow rate of 0.75 mL/min.  Detection was made at 313 nm.  The 
results of the analysis were expressed in µg of KCR per mL of 
plasma. 
 
Calibration curve: The calibration curve was obtained with mouse 
plasma samples spiked with known amounts of KCR stock solution 
in ethanol, and each analyte was extracted according to the protocol 
described above. The calibration curve was obtained by plotting the 
peak area against its concentration in 5 spiked plasma standards 
(18.75, 6.25, 2.5, 1.25, 0.25 µg/mL) and performing a linear 
regression analysis.  
 
During the method development, we tried methanol and acetonitrile 
for sample preparation, but the recovery percentages were low; 
ethanol yielded better results in extracting KCR from plasma 
samples. 
 
The data gathered allow detection of KCR over a 100-fold range of 
concentrations. The method developed here was validated according 
to the U.S. Pharmacopoeia [20] and the analytical performance 
parameters considered were specificity (selectivity), linearity, 
accuracy, precision, sensitivity, stability and ruggedness; the 
analytical details are shown below: 
 
(1) Specificity (selectivity): The absorption spectrum of KCR 
showed a maximum absorption at 313 nm and was chosen for 
quantitative analysis; there was no interfering peak from 
plasma. A typical chromatogram of KCR at 313 nm (Figure 2) 
consisted of a group of four peaks, which were identified as 
EZ, ZZ, EE, and ZE, respectively by comparing with individual 
stereoisomeric standards provided by Dr McChesney. The use 
of a UV photodiode array detector allowed the confirmation of 
the identity for KCR both by their retention times (Figure 2) 
and UV spectra. 
 
(2) Linearity: A calibration curve of KCR was prepared to 
determine the linearity of the method over the range of 0.25 – 
18.75 µg/mL. This range was chosen as previous in vitro 
studies have indicated a mean inhibitory concentration (MIC) 
in the order of 1 – 4 µg/mL for  KCR.  Integrated  peak  areas  
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Figure 2: Representative chromatogram of KCR (10 µL injection). 
 
(summed for the 4 separate peaks) were plotted against analyte 
concentration, and linear regression was performed by the 
least-squares method. The calibration curve generated using 
plasma as matrix showed a square of correlation coefficient of 
0.9978 (Figure 3).  
 
(3) Accuracy: The accuracy of the analytical method was 
determined by application of the method to analyte of known 
concentrations. Two spiked plasma samples (7.50 and 3.75 
µg/mL) were prepared and the assay results were 7.49 and 3.75 
µg/mL, indicating a recovery of 99.9 and 99.8% respectively. 
Therefore, the method is accurate. 
 
(4) Precision: The precision of the analytical method was 
determined by analyzing a plasma sample spiked with 16 
µg/mL of KCR injected 6 times. Peak areas were considered 
for the determination. The precision, expressed as the percent 
coefficient of variation (CV), was 0.71% indicating that the 
method is precise. 
 
(5)  Sensitivity: The limit of detection (LOD) and the limit of 
quantification (LOQ) were obtained by first injecting 6 
replicates of a sample at 0.25 g/mL; the standard deviation 
(StDev) was multiplied by 3.3 and by 10 and the calibration 
curve was used to obtain the LOD and LOQ, respectively. At 
313 nm, the LOD for KCR was 0.021 g/mL and the LOQ was 
0.272 g/mL. 
 
(6)  Ruggedness: Ruggedness was shown by assaying spiked  
plasma samples on 2 consecutive days employing the 
corresponding linearity curve generated on the day the    
sample was assayed. As shown in Table 1, intra- and inter-day 
assay results of a particular  sample  are  essentially  the  same, 
 
Figure 3: Linearity of KCR in mouse plasma  
 
indicating an acceptable ruggedness of the method for intra- 
and inter-day assay studies. In addition, a spiked sample       
(16 µg/mL) was analyzed using 3 different flow rates      
and/or mobile phase. As shown in Table 1, when the flow rate 
was reduced/increased to 0.65/0.8 mL/min, as compared with 
the normal 0.75 mL/min, the recoveries were 100.3 and 
100.3% (intraday). As shown in Table 1, at the same flow rate 
(0.75, 0.6 or 0.8 mL/min), the intra-day recovery rates were   
all within 2% of the control. Furthermore, when both the 
mobile phase and flow rate were modified to become 
methanol/acetonitrile/aqueous formic acid (0.3%), 60/3/37, 
v/v, at 0.75 mL/min, the recoveries were 99.2% and 98.3% for 
replicate assays. The results indicate that the present method is 
rugged with respect to minor changes of the flow rate and 
mobile phase. In addition, the results showed that the samples, 
as prepared herein, were stable for at least 2 days.  
 
Table 1: Ruggedness of the method and sample stability. 
 
Flow Rate (mL/min) 0.75 0.65 0.80 
Day 0 Control 100.3 100.3 
Day 0, night  
(intra-day) 
98.3 98.8 98.3 
Day 1 99.2 98.2 99.7 
Ruggedness and stability are shown in % recovery. 
 
In summary, we have successfully developed a simple method to 
determine KCR in plasma. We have shown that each of the 
parameters discussed above provides a good basis for further 
biological evaluation of KCR and the method described herein is 
suitable for analyzing plasma samples of KCR. The method is 
useful for future studies to evaluate both the pharmacokinetics and 
therapeutic efficacy of KCR in infected mice. 
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